Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTOR NASDAQ:DYAI NASDAQ:INMB NASDAQ:KALA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$0.55-0.4%$0.71$0.49▼$2.37$51.51M3.47172,845 shs26,568 shsDYAIDyadic International$1.12-0.9%$0.90$0.65▼$1.60$40.81M1.15180,701 shs269,942 shsINMBINmune Bio$1.76+1.4%$1.55$1.09▼$3.19$46.95M0.97559,394 shs57,120 shsKALAKALA BIO$0.65-3.2%$2.01$0.59▼$1,030.00$12.55M-2.35131,365 shs22,225 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology-1.10%-2.46%-11.18%-35.86%-71.78%DYAIDyadic International-5.04%-6.61%+41.07%+39.49%+2.73%INMBINmune Bio+6.79%-13.07%+21.83%+23.57%-36.16%KALAKALA BIO+5.74%-10.57%-73.39%-88.29%-99.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$0.55-0.4%$0.71$0.49▼$2.37$51.51M3.47172,845 shs26,568 shsDYAIDyadic International$1.12-0.9%$0.90$0.65▼$1.60$40.81M1.15180,701 shs269,942 shsINMBINmune Bio$1.76+1.4%$1.55$1.09▼$3.19$46.95M0.97559,394 shs57,120 shsKALAKALA BIO$0.65-3.2%$2.01$0.59▼$1,030.00$12.55M-2.35131,365 shs22,225 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology-1.10%-2.46%-11.18%-35.86%-71.78%DYAIDyadic International-5.04%-6.61%+41.07%+39.49%+2.73%INMBINmune Bio+6.79%-13.07%+21.83%+23.57%-36.16%KALAKALA BIO+5.74%-10.57%-73.39%-88.29%-99.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.33Hold$6.00983.03% UpsideDYAIDyadic International 2.33Hold$3.00167.86% UpsideINMBINmune Bio 2.50Moderate BuyN/AN/AKALAKALA BIO 2.00Hold$1,158.33178,379.71% UpsideCurrent Analyst Ratings BreakdownLatest KALA, DYAI, CTOR, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026INMBINmune Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/14/2026CTORCitius Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/30/2026CTORCitius Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026KALAKALA BIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/16/2026CTORCitius Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/11/2026INMBINmune Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius Oncology$5.61M9.18N/AN/A$0.54 per share1.03DYAIDyadic International$3.09M13.21N/AN/A$0.03 per share37.33INMBINmune BioN/AN/AN/AN/A$0.88 per shareN/AKALAKALA BION/AN/AN/AN/A$12.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius Oncology-$24.76M-$0.47N/AN/AN/AN/A-99.47%-42.16%8/18/2026 (Estimated)DYAIDyadic International-$7.36M-$0.23N/AN/AN/A-192.40%-1,005.45%-77.64%8/12/2026 (Estimated)INMBINmune Bio-$45.93M-$1.67N/AN/AN/AN/A-103.03%-77.66%8/6/2026 (Estimated)KALAKALA BIO-$26.98M-$96.14N/AN/AN/AN/A-1,336.10%-94.85%8/6/2026 (Estimated)Latest KALA, DYAI, CTOR, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026Q3 2026CTORCitius Oncology-$0.04N/AN/AN/A$5.83 millionN/A8/12/2026Q2 2026DYAIDyadic International-$0.03N/AN/AN/A$1.03 millionN/A8/6/2026Q2 2026INMBINmune Bio-$0.2067N/AN/AN/A$1.16 millionN/A8/6/2026Q2 2026KALAKALA BIO-$6.00N/AN/AN/AN/AN/A5/15/2026Q2 2026CTORCitius Oncology-$0.01-$0.27-$0.26-$0.27$7.00 million$1.67 million5/15/2026Q1 2026KALAKALA BIO-$8.50-$0.14+$8.36-$0.14N/AN/A5/13/2026Q1 2026DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$0.90 million$1.11 million5/7/2026Q1 2026INMBINmune Bio-$0.2450-$0.20+$0.0450-$0.20$1.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.110.500.12DYAIDyadic International4.082.422.42INMBINmune BioN/A4.244.24KALAKALA BION/A7.917.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%DYAIDyadic International27.95%INMBINmune Bio12.72%KALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipCTORCitius Oncology9.80%DYAIDyadic International20.90%INMBINmune Bio21.40%KALAKALA BIO2.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A92.98 million83.87 millionN/ADYAIDyadic International736.44 million28.82 millionOptionableINMBINmune Bio1026.59 million20.90 millionOptionableKALAKALA BIO3019.34 million18.91 millionNot OptionableKALA, DYAI, CTOR, and INMB HeadlinesRecent News About These CompaniesKALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 markMay 8, 2026 | msn.comKALA BIO Announces Reverse Stock SplitMay 7, 2026 | globenewswire.comHow smart traders spot penny stock breakouts fastMay 1, 2026 | msn.comKala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic MedicineApril 21, 2026 | globenewswire.comKala Bio Delays 2025 Annual Report FilingApril 6, 2026 | theglobeandmail.comKala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and ...April 1, 2026 | caledonianrecord.comCKala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development OpportunitiesApril 1, 2026 | globenewswire.comKALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now LiveMarch 30, 2026 | globenewswire.comEXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform LaunchMarch 30, 2026 | benzinga.comRed Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | markets.businessinsider.comRed Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | globenewswire.comRed Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug CandidateMarch 18, 2026 | newsfilecorp.comNAI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market NarrativeMarch 11, 2026 | markets.businessinsider.comKala Bio chases 'Palantir for biotech' dream with new AI platformMarch 11, 2026 | msn.comYounet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research AgentsMarch 11, 2026 | newsfilecorp.comNKala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution AcceleratesMarch 11, 2026 | globenewswire.comStock Trend Capital Provides Younet AI Investment UpdateMarch 9, 2026 | newsfilecorp.comNKala Bio rises on plans to leverage AIMarch 4, 2026 | seekingalpha.comKALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development ...March 4, 2026 | markets.businessinsider.comKALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”March 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026The Ugliest Stocks in the Market Just Got a Very Expensive Vote of ConfidenceBy Bridget Bennett | July 20, 2026SanDisk’s Volatility May Be Telling Bulls What They Want to HearBy Sam Quirke | July 2, 2026IQM's Nasdaq Debut Could Change the Quantum Race for D-WaveBy Nathan Reiff | July 10, 2026Is the Memory Rally Still Alive After the Semiconductor Sell-Off?By Jessica Mitacek | July 2, 2026KALA, DYAI, CTOR, and INMB Company DescriptionsCitius Oncology NASDAQ:CTOR$0.55 0.00 (-0.36%) As of 12:06 PM Eastern This is a fair market value price provided by Massive. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Dyadic International NASDAQ:DYAI$1.12 -0.01 (-0.88%) As of 12:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.INmune Bio NASDAQ:INMB$1.76 +0.03 (+1.45%) As of 12:32 PM Eastern This is a fair market value price provided by Massive. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.KALA BIO NASDAQ:KALA$0.65 -0.02 (-3.22%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Whirlpool’s Report May Show How Frozen the Housing Market Really Is 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest? Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
